Acadia Pharmaceuticals, Inc. (ACAD) Posts Q1 Loss of 12c/Share
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $25.97 +3.06%
Revenue Growth %: +11.8%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
CRMT, More
Revenue Growth %: +11.8%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q1 EPS of ($0.12), $0.01 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $450 thousand versus the consensus estimate of $500 thousand.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Six Flags names Mark Pauls as chief operating officer
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
